Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Sep;2(3):319-22.
doi: 10.1159/000332424. Epub 2011 Sep 27.

Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant

Linda M Meyer  1 , Carl-Ludwig Schönfeld
Affiliations
Case Reports

Cystoid Macular Edema after Complicated Cataract Surgery Resolved by an Intravitreal Dexamethasone 0.7-mg Implant

Linda M Meyer et al. Case Rep Ophthalmol. 2011 Sep.

Abstract

Purpose: To report the effective treatment of cystoid macular edema (CME) following complicated cataract surgery (resulting in Irvine-Gass syndrome) with a dexamethasone 0.7-mg (Ozurdex(®)) intravitreal implant.

Methods: An interventional case report with optical coherence tomography (OCT) scans.

Results: An 83-year-old Caucasian woman was suffering from CME following complicated cataract surgery on her left eye. She had undergone 3 intravitreal injections of dexamethasone 0.4 mg in the 3 months following the surgery without any improvement of visual function. Seven months after the cataract surgery, she received a single intravitreal injection of dexamethasone 0.7 mg (Ozurdex). Four weeks following the injection, her best-corrected visual acuity improved from 0.3 to 0.8. CME resolved with a reduction of central retinal thickness from 393 μm pre-Ozurdex injection to 212 μm post-Ozurdex injection, as measured by OCT scan.

Conclusion: Dexamethasone 0.7 mg (Ozurdex) has proven to be an effective treatment option in retinal vein occlusion and non-infectious uveitis. It can also be considered as off-label treatment in Irvine-Gass syndrome.

Keywords: Cystoid macular edema; Dexamethasone 0.7 mg; Irvine-Gass syndrome; Ozurdex®.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
OCT scan of CME following complicated cataract surgery. The infrared picture shows retinal localization. CME was refractory to treatment with 3 intravitreal injections of dexamethasone 0.4 mg. Central retinal thickness was 393 μm.
Fig. 2
Fig. 2
Resolved macular edema 4 weeks following an intravitreal injection of a dexamethasone 0.7-mg implant (Ozurdex). The infrared picture shows retinal localization. Central retinal thickness was 212 μm.
Fig. 3
Fig. 3
Follow-up examination 120 days after Ozurdex injection. The infrared picture shows retinal localization. Central retinal thickness was 210 μm.
See this image and copyright information in PMC

References

    1. Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, L Wu, Pan-American Collaborative Retina Study Group Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116:1481–1487. - PubMed
    1. Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg. 1995;21:59–63. - PubMed
    1. Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema: 2010 update. Retina. 2011;31:4–12. - PubMed
    1. Sivaprasad S, Bunce C, Wormland R. Non-steroidal anti-inflammatory agents for cystoid macular edema following cataract surgery: a systematic review. Br J Ophthalmol. 2005;89:1420–1422. - PMC - PubMed
    1. Herrero-Vanell R, Cardillo JA, Kuppermann BD. Clinical applications for the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139–146. - PMC - PubMed

Publication types